Connect with us

Biotechnology

Zota Health Care Limited (zota) Catalyzes Brand Expansion with Mr. Akshay Kumar as Brand Ambassador

Zota Health Care Limited (ZOTA) announces brand expansion with Mr. Akshay Kumar as brand ambassador for UGO Generic, enhancing national presence.

seema chauhan author

Published

on

Zota Health Care Limited ZOTA Q2fy22 Brand Expansion

Zota Health Care Limited (NSE: ZOTA) is proud to announce the appointment of Mr. Akshay Kumar, legendary actor, fitness icon, philanthropist, and entrepreneur, as the brand ambassador for the company and its new brand, UGO Generic. This collaboration marks a defining milestone for Zota Health Care Limited as it elevates its national presence and deepens consumer trust across India.

Strategic Brand Expansion

UGO Generic, a B2B and B2C brand, will offer high-quality generic medicines on a PAN India basis through its owned stores and ~12.5 lakhs retail pharmacies. Mr. Akshay Kumar’s association adds immense strength and mass connect as we advance our vision of making affordable, high-quality generic medicines accessible across India.

Alignment with Company Values

With his unmatched reputation for discipline, resilience, and enduring excellence, Mr. Akshay Kumar embodies the values that guide Zota Health Care Limited and UGO Generic —trust, reach, and a steadfast mission to make quality and affordable healthcare available to every home in India. Commenting on operational development, Mr. Ketankumar Zota, Chairman, Zota Health Care Limited said, “We are delighted to welcome Mr. Akshay Kumar to the Zota family. His influence extends far beyond cinema, making him a widely respected figure admired for his discipline, reliability, and strong personal integrity. These qualities closely align with our mission of making healthcare affordable and accessible for all.”

As Zota Health Care Limited continues to innovate and expand its reach, the partnership with Mr. Akshay Kumar is expected to enhance the brand’s presence and drive stronger growth, wider reach, and deeper impact across India.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Zota Health Care LImited

Zota Health Care LImited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

ZOTA
Healthcare › Biotechnology
CONSOLIDATING DOWN
40
Fundamental
72
Technical
56
Overall

1W +1.1%
1M -8.64%
3M +15.85%
Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Zota falls 11.8% over three months and has not found a floor yet. Margins of 15.4% are above average but show signs of plateauing — watch for further pressure. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock holds at 35% of its 52-week range with RSI at 41. In other words, neither side has a clear edge right now. Revenue grows at 30.7% CAGR and the PEG stands at 99.00. The growth does not match the price the market asks. Furthermore, flat price action adds no technical catalyst. A lower price or faster revenue growth would improve the odds. Check Fundamentals of Zota Health Care LImited.

Biotechnology

Dishman Carbogen Amcis Limited (dcal) Q2fy27 Results: Revenue Down 22.8% Yoy

Dishman Carbogen Amcis Limited (NSE: DCAL) reports Q2FY27 results with a 22.8% YoY revenue decline, driven by lower CDMO segment revenue.

Deputy Editor, Equities for tradealone

Published

on

Dishman Carbogen Amcis Limited DCAL Q2fy27 Results

Dishman Carbogen Amcis Limited (NSE: DCAL) has released its financial results for the second quarter of FY27, ending September 30, 2026. The company reported a net revenue of ₹ 6,527 million for Q2FY27, marking a 22.8% year-on-year decline compared to ₹ 8,463 million in Q2FY26. This decline is primarily attributed to lower revenue from the Contract Development and Manufacturing Organisation (CDMO) segment.

Key Financial Highlights

The EBITDA margin for Q2FY27 stood at 9.1%, significantly lower than the 22.8% recorded in the same quarter of the previous fiscal year. The EBITDA for Q2FY27 was ₹ 459.6 million, a sharp decrease from ₹ 1,488.9 million in Q2FY26. The company’s EBITDA margin for the first half of FY27 was 8.9%, down from 21.3% in H1FY26.

Segment Performance

The CDMO segment revenue for Q2FY27 was ₹ 3,887.5 million, a 23.7% decrease from ₹ 5,094.0 million in Q2FY26. The decline is mainly due to lower development revenue and the rescheduling of project deliverables worth approximately CHF 10 million to H2FY27. On the other hand, the marketable molecules segment revenue increased by 6.6% year-on-year to ₹ 1,186.2 million, supported by higher sales of Quaternary compounds.

However, the overall revenue for H1FY27 was ₹ 11,805 million, down 12.9% compared to ₹ 13,607 million in H1FY26. The CDMO segment revenue for H1FY27 was ₹ 9,290.4 million, a 17.1% decrease from ₹ 11,206.4 million in H1FY26, primarily due to lower development revenue. The marketable molecules segment revenue for H1FY27 was ₹ 2,559.7 million, up 2.4% from ₹ 2,400.6 million in H1FY26, driven by higher sales of Quaternary compounds.

As a result, the company’s net profit after tax (PAT) for Q2FY27 was a loss of ₹ 667.3 million, compared to a profit of ₹ 652.7 million in Q2FY26. For H1FY27, the PAT was a loss of ₹ 1,246.1 million, compared to a profit of ₹ 886.8 million in H1FY26.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Dishman Carbogen Amcis Limited

Dishman Carbogen Amcis Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

DCAL
Healthcare › Biotechnology
APPROACHING SUPPORT
38
Fundamental
42
Technical
41
Overall

1W -16.68%
1M -7.07%
3M -20.82%
P/E: 135.2 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Dishman falls 9.3% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 2 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. The stock gains 13.0% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Price climbs recently despite 7.5% revenue growth and a PEG of 99.00. Consequently, either institutions position ahead of improvement or the move fades when earnings disappoint. Treat this as a trading signal, not an investment thesis. Check Fundamentals of Dishman Carbogen Amcis Limited.

Continue Reading

BIOCON

Biocon Limited Gets U.S. FDA Approval for Pebrilzo™ (pertuzumab-qcay) Injection

Biocon Limited (BIOCON) receives U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta®, expanding its oncology portfolio.

kuldeep yadav tradealone

Published

on

Biocon Limited Biocon FDA Approval Pebrilzo

Biocon Limited (BIOCON) announced today that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo™ (pertuzumab-qcay), a biosimilar of the reference product Perjeta®. This marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. Pebrilzo™ is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells. The FDA approval further strengthens Biocon’s oncology portfolio, now totaling five biosimilar therapies for cancer in the United States.

Expanding Access to Affordable Biologics

Shreehas Tambe, CEO & Managing Director, Biocon Limited, said, “The U.S. FDA approval of Pebrilzo™, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive U.S. FDA approval, Pebrilzo™ strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines.”

Strengthening Oncology Portfolio

Pebrilzo™ will join Biocon’s robust portfolio of oncology therapies, which includes Ogivri® (trastuzumab-dkst), Jobevne® (bevacizumab-nwgd), Fulphila® (pegfilgrastim-jmdb), and Aukelso® (denosumab-kyqq). Building on this foundation, Biocon’s growing oncology pipeline includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab, and pembrolizumab, spanning HER2-directed therapy and immuno-oncology.

As a result, Biocon’s oncology strategy combines an established portfolio with continued development across additional treatment approaches, addressing the ongoing need for treatment options in this area.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

BIOCON
Healthcare › Biotechnology
—
52
Fundamental
56
Technical
54
Overall

1W -1.71%
1M +3.72%
3M -12.09%
P/E: 121.5 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Biocon falls 12.7% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 3.8% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Continue Reading

BIOCON

Biocon Limited Q2 FY27: Revenue Up 2%, Ebitda Margin Declines

Biocon Limited’s Q2 FY27 results show a 2% revenue increase, with EBITDA margin decline; strong biosimilars and generics performance.

preety tomer tradealone

Published

on

Biocon Limited Biocon Q2 FY27 Results

Biocon Limited (BIOCON) reported its Q2 FY27 results, showing a 2% increase in revenue to ₹4,423 Cr compared to ₹4,389 Cr in the same period last year. The company’s EBITDA margin, however, declined to 20% from 22% in Q2 FY26. The focus remains on translating growth into improved margins, free cash flow, debt reduction, and higher returns on capital.

Biosimilars Performance

The Biosimilars segment recorded revenue of ₹2,809 Cr, up 3% YoY. EBITDA stood at ₹623 Cr with a 22% margin. The segment’s performance was impacted by the timing of revenue recognition on certain shipments. The 10-year Pertuzumab partnership in Brazil provides long-term revenue visibility.

Generics Segment

The Generics segment saw a 10% YoY revenue growth to ₹774 Cr. EBITDA margin expanded by over 700bps YoY to 8%. Liraglutide is gaining traction across markets, strengthening the complex injectables portfolio.

Services Division

The Services division revenue stood at ₹833 Cr, up 13% QoQ. EBITDA margin improved by 500bps QoQ to 20%. The division expects further improvement in the second half of the fiscal year.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

BIOCON
Healthcare › Biotechnology
—
52
Fundamental
56
Technical
54
Overall

1W -1.71%
1M +3.72%
3M -12.09%
P/E: 121.5 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Biocon drops 20.1% over three months and trades near its 52-week lows. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 19 of recent sessions versus 11 for buyers, so the pressure has not fully lifted. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Continue Reading

Trending

Exit mobile version